BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. Journal of the American College of Cardiology 2002;39:1414-21. [DOI: 10.1016/s0735-1097(02)01773-4] [Cited by in Crossref: 108] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Foley PW, Leyva F, Frenneaux MP. What is treatment success in cardiac resynchronization therapy? Europace 2009;11 Suppl 5:v58-65. [PMID: 19861392 DOI: 10.1093/europace/eup308] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 4.0] [Reference Citation Analysis]
2 Hawkins NM. Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction - the importance of left ventricular remodelling. Eur J Heart Fail 2019;21:370-2. [PMID: 30592366 DOI: 10.1002/ejhf.1401] [Reference Citation Analysis]
3 Pichler G, Grau-Perez M, Tellez-Plaza M, Umans J, Best L, Cole S, Goessler W, Francesconi K, Newman J, Redon J, Devereux R, Navas-Acien A. Association of Arsenic Exposure With Cardiac Geometry and Left Ventricular Function in Young Adults. Circ Cardiovasc Imaging 2019;12:e009018. [PMID: 31060373 DOI: 10.1161/CIRCIMAGING.119.009018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
4 Mazur W, Chung ES. The role of echocardiography in cardiac resynchronization therapy. Curr Heart Fail Rep 2009;6:37-43. [PMID: 19265591 DOI: 10.1007/s11897-009-0007-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
5 Mantarro S, Rossi M, Bonifazi M, D'Amico R, Blandizzi C, La Vecchia C, Negri E, Moja L. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med 2016;11:123-40. [PMID: 26712595 DOI: 10.1007/s11739-015-1362-x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
6 Armenian SH, Gelehrter SK, Chow EJ. Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer. Cardiol Res Pract 2012;2012:713294. [PMID: 22928146 DOI: 10.1155/2012/713294] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
7 Fornwalt BK, Sprague WW, BeDell P, Suever JD, Gerritse B, Merlino JD, Fyfe DA, León AR, Oshinski JN. Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 2010;121:1985-91. [PMID: 20421518 DOI: 10.1161/CIRCULATIONAHA.109.910778] [Cited by in Crossref: 211] [Cited by in F6Publishing: 48] [Article Influence: 17.6] [Reference Citation Analysis]
8 Tanaka K, Essick EE, Doros G, Tanriverdi K, Connors LH, Seldin DC, Sam F. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis. J Am Heart Assoc 2013;2:e005868. [PMID: 23537813 DOI: 10.1161/JAHA.112.005868] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
9 Weintraub WS, Lüscher TF, Pocock S. The perils of surrogate endpoints. Eur Heart J 2015;36:2212-8. [PMID: 25975658 DOI: 10.1093/eurheartj/ehv164] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
10 Andrukhova O, Salama M, Rosenhek R, Gmeiner M, Perkmann T, Steindl J, Aharinejad S. Serum glutathione S-transferase P1 1 in prediction of cardiac function. J Card Fail 2012;18:253-61. [PMID: 22385947 DOI: 10.1016/j.cardfail.2011.11.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
11 Chakravarty T, Makkar RR, Ascheim DD, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith RR, Lima JA, Pogoda JM, Marbán L, Henry TD. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. Cell Transplant 2017;26:205-14. [PMID: 27543900 DOI: 10.3727/096368916X692933] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
12 Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail 2018;5:685-94. [PMID: 29660263 DOI: 10.1002/ehf2.12283] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
13 Iyngkaran P, Liew D, McDonald P, Thomas MC, Reid C, Chew D, Hare DL. Phase 4 Studies in Heart Failure - What is Done and What is Needed? Curr Cardiol Rev. 2016;12:216-230. [PMID: 27280303 DOI: 10.2174/1573403x12666160606121458] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
14 Abbate A, Van Tassell BW, Biondi-Zoccai G, Kontos MC, Grizzard JD, Spillman DW, Oddi C, Roberts CS, Melchior RD, Mueller GH, Abouzaki NA, Rengel LR, Varma A, Gambill ML, Falcao RA, Voelkel NF, Dinarello CA, Vetrovec GW. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. Am J Cardiol 2013;111:1394-400. [PMID: 23453459 DOI: 10.1016/j.amjcard.2013.01.287] [Cited by in Crossref: 217] [Cited by in F6Publishing: 209] [Article Influence: 24.1] [Reference Citation Analysis]
15 Wessler BS, McCauley M, Morine K, Konstam MA, Udelson JE. Relation between therapy-induced changes in natriuretic peptide levels and long-term therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. Eur J Heart Fail 2019;21:613-20. [PMID: 30919541 DOI: 10.1002/ejhf.1411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
16 Spertus JA, Jones PG, Masoudi FA, Rumsfeld JS, Krumholz HM. Factors associated with racial differences in myocardial infarction outcomes. Ann Intern Med 2009;150:314-24. [PMID: 19258559 DOI: 10.7326/0003-4819-150-5-200903030-00007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
17 Ghayal P, Haider A, Aronow WS, Goldberg Y, Bello R, Garcia MJ, Spevack DM. Long-term echocardiographic changes in left ventricular size and function following surgery for severe mitral regurgitation. Med Sci Monit 2012;18:CR209-14. [PMID: 22460092 DOI: 10.12659/msm.882620] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
18 Khanam SS, Son JW, Lee JW, Youn YJ, Yoon J, Lee SH, Kim JY, Ahn SG, Ahn MS, Yoo BS. Prognostic value of short-term follow-up BNP in hospitalized patients with heart failure. BMC Cardiovasc Disord 2017;17:215. [PMID: 28774268 DOI: 10.1186/s12872-017-0632-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
19 Goenka L, George M, Selvarajan S. End points in heart failure-are we doing it right? Eur J Clin Pharmacol 2017;73:651-9. [PMID: 28280889 DOI: 10.1007/s00228-017-2228-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
20 Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE. Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol 2010;56:392-406. [PMID: 20650361 DOI: 10.1016/j.jacc.2010.05.011] [Cited by in Crossref: 259] [Cited by in F6Publishing: 220] [Article Influence: 21.6] [Reference Citation Analysis]
21 Zemrak F, Ahlman MA, Captur G, Mohiddin SA, Kawel-Boehm N, Prince MR, Moon JC, Hundley WG, Lima JA, Bluemke DA, Petersen SE. The relationship of left ventricular trabeculation to ventricular function and structure over a 9.5-year follow-up: the MESA study. J Am Coll Cardiol 2014;64:1971-80. [PMID: 25440091 DOI: 10.1016/j.jacc.2014.08.035] [Cited by in Crossref: 121] [Cited by in F6Publishing: 91] [Article Influence: 15.1] [Reference Citation Analysis]
22 Savarese G, Uijl A, Ouwerkerk W, Tromp J, Anker SD, Dickstein K, Hage C, Lam CSP, Lang CC, Metra M, Ng LL, Orsini N, Samani NJ, van Veldhuisen DJ, Cleland JGF, Voors AA, Lund LH. Biomarker changes as surrogate endpoints in early-phase trials in heart failure with reduced ejection fraction. ESC Heart Fail 2022. [PMID: 35388650 DOI: 10.1002/ehf2.13917] [Reference Citation Analysis]
23 Rocha LA, Petriz BA, Borges DH, Oliveira RJ, de Andrade RV, Domont GB, Pereira RW, Franco OL. High molecular mass proteomics analyses of left ventricle from rats subjected to differential swimming training. BMC Physiol 2012;12:11. [PMID: 22950628 DOI: 10.1186/1472-6793-12-11] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
24 Coffman E, Richmond-Bryant J. Multiple biomarker models for improved risk estimation of specific cardiovascular diseases related to metabolic syndrome: a cross-sectional study. Popul Health Metr 2015;13:7. [PMID: 25788869 DOI: 10.1186/s12963-015-0041-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
25 AlTurki A, Proietti R, Dawas A, Alturki H, Huynh T, Essebag V. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2019;19:18. [PMID: 30646857 DOI: 10.1186/s12872-019-0998-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
26 Nelson CA, Case C, McCrohon J, Marwick TH. Relationship of extent and nature of dysfunctional myocardium to brain natriuretic peptide in patients with ischemic left ventricular dysfunction. Int J Cardiovasc Imaging 2005;21:295-300; discussion 301-2. [PMID: 16015444 DOI: 10.1007/s10554-004-3565-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
27 Sato Y, Kita T, Takatsu Y, Kimura T. Biochemical markers of myocyte injury in heart failure. Heart 2004;90:1110-3. [PMID: 15367501 DOI: 10.1136/hrt.2003.023895] [Cited by in Crossref: 80] [Cited by in F6Publishing: 61] [Article Influence: 4.4] [Reference Citation Analysis]